Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Mielke, Michelle M ^a   Maetzler, Walter ^b   Haughey, Norman J ^c   Bandaru, Veera V R ^c   Savica, Rodolfo ^a   Deuschle, Christian ^b   Gasser, Thomas ^b   Hauser, Ann Kathrin ^b   Gräber Sultan, Susanne ^b   Schleicher, Erwin ^d   Berg, Daniela ^b   Liepelt Scarfone, Inga ^b  

^a MAYO CLINIC   (United States)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; LACTOSYLCERAMIDE; MONOHEXOSYLCERAMIDE; SPHINGOLIPID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; FEMALE; GBA GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; PARKINSON DISEASE; PILOT STUDY;

AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CERAMIDES; CEREBROSIDES; COGNITION; DEMENTIA; FEMALE; GENOTYPE; GLUCOSYLCERAMIDASE; HUMANS; LACTOSYLCERAMIDES; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84884264199     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073094     Document Type: Article

References (28)

1. Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE, (2000) alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem 275: 34328-34334.
2. Sharon R, Goldberg MS, Bar-Josef I, Betensky RA, Shen J, et al. (2001) alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A 98: 9110-9115.
3. Bras J, Singleton A, Cookson MR, Hardy J, (2008) Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease. FEBS J 275: 5767-5773.
4. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, et al. (2011) Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146: 37-52.
5. Lee YJ, Wang S, Slone SR, Yacoubian TA, Witt SN, (2011) Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease. PLoS ONE 6: e15946.
6. Beutler E, (1992) Gaucher disease: new molecular approaches to diagnosis and treatment. Science 256: 794-799.
7. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361: 1651-1661.
8. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, et al. (2012) GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 79: 1944-1950.
9. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, et al. (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132: 1783-1794.
10. Brockmann K, Srulijes K, Hauser AK, Schulte C, Csoti I, et al. (2011) GBA-associated PD presents with nonmotor characteristics. Neurology 77: 276-280.
11. Aarsland D, Kurz MW, (2010) The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 289: 18-22.
12. Balzer-Geldsetzer M, Costa AS, Kronenburger M, Schulz JB, Roske S, et al. (2011) Parkinson's disease and dementia: a longitudinal study (DEMPARK). Neuroepidemiology 37: 168-176.
13. Gibb WR, Lees AJ, (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 745-752.
14. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, et al. (2012) Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 27: 349-356.
15. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, et al. (2007) Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 22: 2314-2324.
16. Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, et al. (2004) Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 55: 257-267.
17. Bandaru VV, McArthur JC, Sacktor N, Cutler RG, Knapp EL, et al. (2007) Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology 68: 1481-1487.
18. Mielke MM, Bandaru VVR, Xia J, Haughey NJ, Fried LP, et al. (2012) Serum ceramides increase the risk of Alzheimer disease: The Women's Health and Aging Study II. Neurology 79: 633-641.
19. Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyketsos CG, et al. (2010) Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 31: 17-24.
20. Yap TL, Gruschus JM, Velayati A, Westbroek W, Goldin E, et al. (2011) Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem 286: 28080-28088.
21. Sofic E, Denisova N, Youdim K, Vatrenjak-Velagic V, De Filippo C, et al. (2001) Antioxidant and pro-oxidant capacity of catecholamines and related compounds. Effects of hydrogen peroxide on glutathione and sphingomyelinase activity in pheochromocytoma PC12 cells: potential relevance to age-related diseases. J Neural Transm 108: 541-557.
22. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, et al. (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A 94: 7531-7536.
23. Levenson CW, Cutler RG, Ladenheim B, Cadet JL, Hare J, et al. (2004) Role of dietary iron restriction in a mouse model of Parkinson's disease. Exp Neurol 190: 506-514.
24. France-Lanord V, Brugg B, Michel PP, Agid Y, Ruberg M, (1997) Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease. J Neurochem 69: 1612-1621.
25. Darios F, Corti O, Lucking CB, Hampe C, Muriel MP, et al. (2003) Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12: 517-526.
26. da Costa CA, Ancolio K, Checler F, (2000) Wild-type but not Parkinson's disease-related ala-53 → Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. J Biol Chem 275: 24065-24069.
27. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M, Rosado L, et al. (2012) Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 78: 1434-1440.
28. Gracia-Garcia P, Rao V, Haughey NJ, Ratnam Banduru VV, Smith G, et al. (2011) Elevated plasma ceramides in depression. J Neuropsychiatry Clin Neurosci 23: 215-218.